Research

2023

• Node-negative colon cancer: histological, molecular, and stromal features predicting disease recurrence. Strous MTA, van der Linden RLA, Gubbels ALHM, Faes TKE, Bosscha K, Bronkhorst CM, Janssen-Heijnen MLG, de Bruïne AP, Vogelaar FJ. Mol Med. 2023 Jun 21;29(1):77. doi: 10.1186/s10020-023-00677-8.
• Tumor-Stroma Ratio in Colorectal Cancer-Comparison between Human Estimation and Automated Assessment. Firmbach D, Benz M, Kuritcyn P, Bruns V, Lang-Schwarz C, Stuebs FA, Merkel S, Leikauf LS, Braunschweig AL, Oldenburger A, Gloßner L, Abele N, Eck C, Matek C, Hartmann A, Geppert CI. Cancers (Basel). 2023 May 9;15(10):2675. doi: 10.3390/cancers15102675.
• Prognostic evaluation of cancer associated fibrosis and tumor budding in colorectal cancer. Khan AA, Malik S, Jacob S, Aden D, Ahuja S, Zaheer S, Ranga S. Pathol Res Pract. 2023 Jun 2;248:154587. doi: 10.1016/j.prp.2023.154587.
• Domain-specific transfer learning in the automated scoring of tumor-stroma ratio from histopathological images of colorectal cancer. Petäinen L, Väyrynen JP, Ruusuvuori P, Pölönen I, Äyrämö S, Kuopio T. PLoS One. 2023 May 26;18(5):e0286270. doi: 10.1371/journal.pone.0286270.
• The prognostic role of tumor budding and tumor-stroma ratio in pulmonary metastasis of colorectal carcinoma. Karjula T, Kemi N, Niskakangas A, Mustonen O, Puro I, Pohjanen VM, Kuopio T, Elomaa H, Ahtiainen M, Mecklin JP, Seppälä TT, Wirta EV, Sihvo E, Väyrynen JP, Yannopoulos F, Helminen O. Eur J Surg Oncol. 2023 Jul;49(7):1298-1306. doi: 10.1016/j.ejso.2023.02.009.

2022

• Value of the Tumor Stroma Ratio and Structural Heterogeneity Measured by a Novel Semi-Automatic Image Analysis Technique for Predicting Survival in Patients with Colon Cancer. Inoue H, Kudou M, Shiozaki A, Kosuga T, Shimizu H, Kiuchi J, Arita T, Konishi H, Komatsu S, Kuriu Y, Morinaga Y, Konishi E, Otsuji E. Dis Colon Rectum. 2022 Dec 15. doi: 10.1097/DCR.0000000000002570. Epub ahead of print
• Prognostic value of desmoplastic stromal reaction, tumor budding and tumor-stroma ratio in stage II colorectal cancer. Fan S, Cui X, Zheng L, Ma W, Zheng S, Wang J, Qi L, Ye Z. J Gastrointest Oncol. 2022 Dec;13(6):2903-2921. doi: 10.21037/jgo-22-758
• Tumour-stroma ratio to predict pathological response to neo-adjuvant treatment in rectal cancer. Strous MTA, Faes TKE, Heemskerk J, Lohman BGPM, Simons PCG, Janssen Heijnen MLG, Vogelaar FJ, de Bruïne AP. Surg Oncol. 2022 Dec;45:101862. doi: 10.1016/j.suronc.2022.101862. Epub 2022 Oct 5
• Correlation of Immunological and Histopathological Features with Gene Expression-Based Classifiers in Colon Cancer Patients. van de Weerd S, Smit MA, Roelands J, Mesker WE, Bedognetti D, Kuppen PJK, Putter H, Tollenaar RAEM, Roodhart JML, Hendrickx W, Medema JP, van Krieken JHJM. Int J Mol Sci. 2022 Oct 21;23(20):12707. doi: 10.3390/ijms232012707
• Vimentin and tumor-stroma ratio for neoadjuvant chemoradiotherapy response prediction in locally advanced rectal cancer. Tian W, Yang Y, Qin Q, Zhang L, Wang Z, Su L, Zeng L, Chen H, Hu L, Hong J, Huang Y, Zhang Q, Zhao H. Cancer Sci. 2022 Oct 11. doi: 10.1111/cas.15610. Epub ahead of print
• Correlation between apparent diffusion coefficient and tumor-stroma ratio in hybrid ¹⁸F-FDG PET/MRI: preliminary results of a rectal cancer cohort study. Hu S, Xing X, Liu J, Liu X, Li J, Jin W, Li S, Yan Y, Teng D, Liu B, Wang Y, Xu B, Du X. Quant Imaging Med Surg. 2022 Aug;12(8):4213-4225. doi: 10.21037/qims-21-938.
• A high tumour-stroma ratio (TSR) in colon tumours and its metastatic lymph nodes predicts poor cancer-free survival and chemo resistance. Strous MTA, Faes TKE, Gubbels ALHM, van der Linden RLA, Mesker WE, Bosscha K, Bronkhorst CM, Janssen-Heijnen MLG, Vogelaar FJ, de Bruïne AP. Clin Transl Oncol. 2022 Jun;24(6):1047-1058.
• The Prognostic Impact of Tumor Border Configuration, Tumor Budding and Tumor Stroma Ratio in Colorectal Carcinoma. Aboelnasr LS, El-Rebey HS, Mohamed A, Abdou AG. Turk Patoloji Derg. 2022 Jun 1.
• Tumor Stroma Ratio and Its Significance in Locally Advanced Colorectal Cancer. Sullivan L, Pacheco RR, Kmeid M, Chen A, Lee H. Curr Oncol. 2022 May 3;29(5):3232-3241.
• Characteristics of tumour stroma in regional lymph node metastases in colorectal cancer patients: a theoretical framework for future diagnostic imaging with FAPI PET/CT. Polack M, Hagenaars SC, Couwenberg A, Kool W, Tollenaar RAEM, Vogel WV, Snaebjornsson P, Mesker WE. Clin Transl Oncol. 2022 Apr 28.

2021

• The Stroma Liquid Biopsy Panel Contains a Stromal-Epithelial Gene Signature Ratio That Is Associated with the Histologic Tumor-Stroma Ratio and Predicts Survival in Colon Cancer. Ravensbergen CJ, Kuruc M, Polack M, Crobach S, Putter H, Gelderblom H, Roy D, Tollenaar RAEM, Mesker WE. Cancers (Basel). 2021 Dec 29;14(1):163.
• Impact of Tumor-Stroma Ratio on the Prognosis of Colorectal Cancer: A Systematic Review. Gao J, Shen Z, Deng Z, Mei L. Front Oncol. 2021 Nov 16;11:738080.
• Semiautomatic analysis of tumor proportion in colon cancer: Lessons from a validation study. Miller S, Bauer S, Schrempf M, Schenkirsch G, Probst A, Märkl B, Martin B. Pathol Res Pract. 2021 Nov;227:153634.
• Combined Assessment of the Tumor-Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer. Ravensbergen CJ, Polack M, Roelands J, Crobach S, Putter H, Gelderblom H, Tollenaar RAEM, Mesker WE. Cells. 2021 Oct 28;10(11):2935.
• Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study. Smit MA, van Pelt GW, Terpstra V, Putter H, Tollenaar RAEM, Mesker WE, van Krieken JHJM. Int J Colorectal Dis. 2021 Sep 17.
• Concurrent Comparison of the Prognostic Values of Tumor Budding, Tumor Stroma Ratio, Tumor Infiltrating Pattern and Lymphocyte-to-Monocyte Ratio in Colorectal Cancer Patients. Zhang Y, Liu Y, Qiu X, Yan B. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211045826.
• The value of the tumour-stroma ratio for predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer: a case control study. Liang Y, Zhu Y, Lin H, Zhang S, Li S, Huang Y, Liu C, Qu J, Liang C, Zhao K, Li Z, Liu Z. BMC Cancer. 2021 Jun 25;21(1):729
• Prognostic Value of Tumor-Stroma Ratio in Rectal Cancer: A Systematic Review and Meta-analysis. Zhu Y, Jin Z, Qian Y, Shen Y, Wang Z. Front Oncol. 2021 May 26;11:685570.
• Increasing Embryonic Morphogen Nodal Expression Suggests Malignant Transformation in Colorectal Lesions and as a Potential Marker for CMS4 Subtype of Colorectal Cancer. Wang X, Liu S, Cao H, Li X, Rong Y, Liu G, Du H, Shen H. Pathol Oncol Res. 2021 Mar 10;27:587029
• Clinicopathological Significances of Tumor-Stroma Ratio (TSR) in Colorectal Cancers: Prognostic Implication of TSR Compared to Hypoxia-Inducible Factor-1α Expression and Microvessel Density. Kang G, Pyo JS, Kim NY, Kang DW. Curr Oncol. 2021 Mar 22;28(2):1314-1324.
• Standardized Assessment of the Tumor-Stroma Ratio in Colorectal Cancer: Interobserver Validation and Reproducibility of a Potential Prognostic Factor. Souza da Silva RM, Queiroga EM, Paz AR, Neves FFP, Cunha KS, Dias EP. Clin Pathol. 2021 Feb 11;14:2632010X21989686.
• The Effect of Quality Control on Accuracy of Digital Pathology Image Analysis. Wright AI, Dunn CM, Hale M, Hutchins GGA, Treanor DE. IEEE J Biomed Health Inform. 2021 Feb;25(2):307-314.

2020

• Tumour-stroma ratio has poor prognostic value in non-pedunculated T1 colorectal cancer: A multi-centre case-cohort study. Dang H, van Pelt GW, Tollenaar RA, Hardwick JC, Hawinkels LJ, Moons LM, Lacle MM, Mesker WE, Boonstra JJ; Dutch T1 CRC Working Group. United European Gastroenterol J. 2020 Nov 19:2050640620975324
• Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. Zunder SM, Perez-Lopez R, Gelderblom H, Tollenaar RA, Nuciforo P, Wasser MN, Mesker WE. Eur J Radiol. 2020 Oct 13;133:109345
• The role of artificial intelligence to quantify the tumour-stroma ratio for survival in colorectal cancer. Smit MA, Mesker WE. EBioMedicine. 2020 Nov;61:103070
• Multiparametric MRI-based radiomics signature for preoperative estimation of tumor-stroma ratio in rectal cancer. Cai C, Hu T, Gong J, Huang D, Liu F, Fu C, Tong T. Eur Radiol. 2020 Nov 12. doi: 10.1007/s00330-020-07403-6. Epub ahead of print. PMID: 33180166.
• Artificial intelligence quantified tumour-stroma ratio is an independent predictor for overall survival in resectable colorectal cancer. Zhao K, Li Z, Yao S, Huang Y, Liang C, Liu Z. EBioMedicine. 2020 Nov;61:103054
• Filling the Gap between Microscopic and Automated Analysis of the Tumor-Stroma Ratio. Van Pelt G, Tollenaar R, Mesker W. Ann Colorectal Res. 2020;8(1):1-4
• The significance of stromal collagen organization in cancer tissue; an in-depth discussion of literature. Zunder SM, Gelderblom H, Tollenaar RA, Mesker WE. Critical Reviews in Oncology/Hematology. 2020 July, 102907
• Prognostic and Predictive Value of the Tumor-Stroma Ratio in STAGE II Colon Cancer. Zunder SM, Gerger A, Gelderblom H, Tollenaar RA, Filipits M, et al. Clinical Oncology and Research. 2020 April.
• Tumor proportion in colon cancer: results from a semiautomatic image analysis approach. Martin B, Banner BM, Schäfer EM, Mayr P, Anthuber M, et al. Virchows Arch. 2020 Feb 19
• Preoperative, biopsy-based assessment of the tumour microenvironment in patients with primary operable colorectal cancer. Park JH, van Wyk H, McMillan DC, Edwards J, Orange C, et al. J Pathol Clin Res. 2020 Jan;6(1):30-39
• Association of the tumour stroma percentage in the preoperative biopsies with lymph node metastasis in colorectal cancer. Fu M, Chen D, Luo F, Li M, Wang Y, et al. Br J Cancer 122, 388–396 (2020).

2019

• Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial. Zunder S, van der Wilk P, Gelderblom H, Dekker T, Mancao C, et al. Cell Oncol (Dordr). 2019 Oct;42(5):717-725.
• The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. van Wyk HC, Roseweir A, Alexander P, Park JH, Horgan PG, et al. Ann Surg Oncol. 2019 Oct 11.
• Tumour Budding and Tumour Stroma Ratio are Reliable Predictors for Death and Recurrence in Elderly Stage I Colon Cancer Patients. Zengin M. Pathol Res Pract. 2019 Nov;215(11):152635
• The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer. Roseweir AK, Clark J, McSorley ST, vanWyk HC, Quinn JA, et al. Int J Cancer. 2019 May 1;144(9):2320-2329.
• Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. Geessink OGF, Baidoshvili A, Klaase JM, Ehteshami Bejnordi B, Litjens GJS, et al. Cellular Oncology. 2019 February.

2018

• Scoring the tumour-stroma ratio in colon cancer: Procedure and recommendations. van Pelt GW, Kjaer-Frifeldt S, van Krieken JHJM, Al Dieri R, Morreau H, Tollenaar RAEM, et al. Virchows Archiv. 2018 Oct; 473(4):405-412
• Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. Zunder SM, van Pelt GW, Gelderblom HJ, Mancao C, Putter H, Tollenaar RA, et al. British Journal of Cancer. 2018
• The tumour-stroma ratio in colon cancer; the biological role and its prognostic impact. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken J, Tollenaar R, et al. Histopathology. 2018 Aug;73(2):197-206.
• The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial. Huijbers A, van Pelt GW, Kerr RS, Johnstone EC, Tollenaar R, Kerr DJ, et al. J Surg Oncol. 2018 Apr;117(5):1043-1048.
• Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer? Eriksen AC, Andersen JB, Lindebjerg J, dePont Christensen R, Jansen TF, Kjaer-Frifeldt S, et al. Diagn Pathology. 2018 Mar;13(1):20
• Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. Hutchins GGA, Treanor D, Wright A, Handley K, Magill L, Tinkler-Hundal E, et al. 2018;72(3):391-404.
• The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. Eriksen AC, Sorensen FB, Lindebjerg J,Hager H, dePont Christensen R, Kjaer-Frifeldt S, et al. International Journal of Colorectal Disease. 2018 Aug;33(8):115-1124
• Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, et al. Br J Surg. 2018 Jan;105(2):e204-e211

2017

• Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer. Jakubowska K, Kisielewski W, Kanczuga-Koda L, Koda M, Famulski W. Oncol Lett. 2017;14(3):3869-77.
• High tumor stroma proportion is a worse prognostic factor in colorectal cancer. Flam J, Gugic D, Bensic M, Tomic S, Rajc J.Acta Clin Croat. 2017 Jan;56(1)73-79.
• Prognostic markers for colorectal cancer; estimating ploidy and stroma. Danielsen HE, Hveem TS, Domingo E, Pradhan M, Kleppe A, Syvertsen RA, et al. Ann Oncol. 2017.
• Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. Hansen TF, Kjaer-Frifeldt S, Lindebjerg J, Rafaelsen SR, Jensen LH, Jakobsen A, et al. Acta Oncol. 2017:1-6.
• Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study. Hynes SO, Coleman HG, Kelly PJ, Irwin S, O’Neill RF, Gray RT, et al. 2017;71(1):12-26.
• Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. Park JH, van Wyk H, Roxburgh CSD, Horgan PG, Edwards J, McMillan DC. Br J Cancer. 2017;116(11):1444-50.
• Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study. Scheer R, Baidoshvili A, Zoidze S, Elferink MAG, Berkel AEM, Klaase JM, et al. World J Gastrointest Oncol. 2017;9(12):466-74.

2016

• Stroma-High Lymph Node Involvement Predicts Poor Survival More Accurately for Patients with Stage III Colon Cancer. Van Pelt GW, Hansen TF,Bastiaannet E, Frifeldt SK, Van Krieken JH, et al. J Med Surg Pathol 2016; 1:116.
• Are disseminated tumor cells in bone marrow and tumor-stroma ratio clinically applicable for patients undergoing surgical resection of primary colorectal cancer? The Leiden MRD study. Vogelaar FJ, van Pelt GW, van Leeuwen AM, Willems JM, Tollenaar RA, Liefers GJ, et al. Cell Oncol (Dordr). 2016;39(6):537-44.

2014

• The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS. Ann Oncol. 2014;25(3):644-51.

2013

• The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, et al. Ann Oncol. 2013;24(1):179-85

2010

• The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, et al. Br J Cancer. 2010;102(10):1519-23.

2009

• Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, et al. Cell Oncol. 2009;31(3):169-78.

2007

• The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, et al. Cell Oncol. 2007;29(5):387-98.

2023

• Tumour-stroma ratio (TSR) in breast cancer: comparison of scoring core biopsies versus resection specimens. Karancsi Z, Hagenaars SC, Németh K, Mesker WE, Tőkés AM, Kulka J. Virchows Arch. 2023 May 18. doi: 10.1007/s00428-023-03555-0. Epub ahead of print.
• Tumor-Stroma Ratio in ER+/HER2- Breast Cancer: Is it a Tool for Treatment Decision? Elmhadi C, Allaoui M, Zerrik M, Oukabli M, Tanz R, Ichou M. Gulf J Oncolog. 2023 May;1(42):14-21. PMID: 37283255. PMID: 37198327.
• A new practical method of estimating tumoral microenvironment parameters of possible prognostic significance in patients with invasive breast carcinoma: Combined microenvironment score. Öztürk Ç, Okcu O, Öztürk SD, Aşkan G, Şen B, Bedir R. Ann Diagn Pathol. 2023 Jun;64:152128. doi: 10.1016/j.anndiagpath.2023.152128. .

2022

• Investigating the role of core needle biopsy in evaluating tumor-stroma ratio (TSR) of invasive breast cancer: a retrospective study. Le MK, Odate T, Kawai M, Oishi N, Kondo T. Breast Cancer Res Treat. 2022 Nov 6. doi: 10.1007/s10549-022-06768-0. Epub ahead of print
• Correlation of Yes-Associated Protein 1 with Stroma Type and Tumor Stiffness in Hormone-Receptor Positive Breast Cancer. Lee Y, Bae SJ, Eun NL, Ahn SG, Jeong J, Cha YJ. Cancers (Basel). 2022 Oct 11;14(20):4971
• Tumour stroma ratio is a potential predictor for 5-year disease-free survival in breast cancer. Yan D, Ju X, Luo B, Guan F, He H, Yan H, Yuan J. BMC Cancer. 2022 Oct 21;22(1):1082
• Standardization of the tumor-stroma ratio scoring method for breast cancer research. Hagenaars SC, Vangangelt KMH, Van Pelt GW, Karancsi Z, Tollenaar RAEM, Green AR, Rakha EA, Kulka J, Mesker WE. Breast Cancer Res Treat. 2022 Jun;193(3):545-553
• Proposal of an automated tumor-stromal ratio assessment algorithm and a nomogram for prognosis in early-stage invasive breast cancer. Xu Q, Chen YY, Luo YH, Zheng JS, Lin ZH, Xiong B, Wang LW. Cancer Med. 2022 Jun 11.
• An easy and practical prognostic parameter: tumor-stroma ratio in Luminal, Her2, and triple-negative breast cancers. Öztürk Ç, Okcu O, Şen B, Bedir R. Rev Assoc Med Bras (1992). 2022 Feb;68(2):227-233.

2021

• Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer. Hagenaars SC, de Groot S, Cohen D, Dekker TJA, Charehbili A, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Pijl H, Putter H, Tollenaar RAEM, Kroep JR, Mesker WE; Dutch Breast Cancer Research Group (BOOG). Int J Cancer. 2021 Sep 1;149(5):1181-1188
• Toward a quantitative method for estimating tumour-stroma ratio in breast cancer using polarized light microscopy. Sprenger J, Murray C, Lad J, Jones B, Thomas G, Nofech-Mozes S, Khorasani M, Vitkin A. Biomed Opt Express. 2021 May 10;12(6):3241-3252
• Prognostic value of Tumor Stroma Ratio in Triple Negative Breast Cancer. Zakhartseva LM, Yanovytska MA. Wiad Lek. 2021;74(3 cz 2):565-571.

2020

• Tumour Stroma Ratio Assessment Using Digital Image Analysis Predicts Survival in Triple Negative and Luminal Breast Cancer. Millar EK, Browne LH, Beretov J, Lee K, Lynch J, Swarbrick A, Graham PH. Cancers (Basel). 2020 Dec 13;12(12):E3749.
• Chemotherapy resistance and stromal targets in breast cancer treatment: a review. van der Spek YM, Kroep JR, Tollenaar RAEM, Mesker WE. Mol Biol Rep. 2020 Oct 1. doi: 10.1007/s11033-020-05853-1. Epub ahead of print. PMID: 33006013.
• 70-Gene Signature and Tumor-Stroma Ratio Select Different Groups of Patients with Breast Cancer at Risk for Recurrence. Smit MA, van Steenhoven JEC, Tollenaar RAEM, van Dalen T, van Diest PJ, et al. Journal of Surgery and Research 3 (2020): 112-118.
• The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. Vangangelt KMH, Green AR, Heemskerk IMF, Cohen D, van Pelt GW, et al. Int J Cancer. 2020 Apr 15;146(8):2296-2304
• Does Tumor Stroma Ratio of Breast Cancer Trucut Biopsy Determine Response to Neoadjuvant Therapy? Mallya V, Singh V, Kaur N, Yadav P, Mandal S, et al. Indian J Pathol Microbiol, 63 (Supplement), S113-S116 Feb 2020
• The intra-tumoural stroma in patients with breast cancer increases with age. Vangangelt KMH, Kramer CJH, Bastiaannet E, Putter H, Cohen D, van Pelt GW, et al. Breast Cancer Res Treat. 2020 Jan;179(1):37-45

2019

• The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, Tollenaar RAEM, Mesker WE. Breast Cancer Res Treat. 2019 Jan;173(1):55-64

2018

• The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients. Vangangelt KMH, Tollenaar LSA, van Pelt GW, de Kruijf EM, Dekker TJA, Kuppen PJK , et al. Int J Cancer. 2018 Jul 6.
• Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma. Vangangelt KMH, van Pelt GW, Engels CC, Putter H, Liefers GJ, Smit V, et al. Breast Cancer Res Treat. 2018 Apr;168(3):601-612.

2017

• The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study. Roeke T, Sobral-Leite M, Dekker TJA, Wesseling J, Smit V, Tollenaar R, et al. Breast Cancer Res Treat. 2017;166(2):435-45.

2014

• The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. Gujam FJ, Edwards J, Mohammed ZM, Going JJ, McMillan DC. Br J Cancer. 2014;111(1):157-65
• The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer.Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB, et al. Br J Cancer  2014; 110 (7):1744-1747.
• Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Dekker TJ, van de Velde CJ, van Pelt GW, Kroep JR, Julien JP, Smit VT, et al. Breast Cancer Res Treat. 2013;139(2):371-9.

2012

• The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA. Eur J Surg Oncol. 2012;38(4):307-13.

2011

• Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies. Jiang P, Chen Y, Liu B. Front Oncol. 2021 Dec 16;11:731409.
• Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, et al. Breast Cancer Res Treat. 2011;125(3):687-96.

2020

• The prognostic value of the tumor-stroma ratio in squamous cell lung cancer, a cohort study. Smit MA, Philipsen MWH, Postmus PE, Putter H, Tollenaar RAEM, Cohen D, Mesker WE. Cancer Treatment and Research Communications. 2020 Nov; 25: 2468-2942

2019

• Intratumoral heterogeneity as measured using the tumor-stroma ratio and PET texture analyses in females with lung adenocarcinomas differs from that of males with lung adenocarcinomas or squamous cell carcinomas. Koh YW, Lee D, Lee SJ, et al. Medicine (Baltimore). 2019 Mar;98(11):e14876

2018

• The ratio of cancer cells to stroma within the invasive area is histologic prognostic parameter of lung adenocarcinoma. Ichikawa T, Aokage K, Sugano M, Miyoshi T, Kojima M, Fujii S, et al. Lung Cancer 2018; 118:30-35.

2017

• Tumour-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival. Xi K, Wen Y, Zhu C, Yu X, Qin R, Zhang X, et al. J Thorac Dis 2017; 9(10):4017-4026.

2015

• Tumor-stroma ratio is an independent predictor for survival in NSCLC. Zhang T, Xu J, Shen H, Dong W, Ni Y, Du J. Int J Clin Exp Pathol. 2015;8(9):11348-55.

2013

• [Tumor-stroma ratio is an independent prognostic factor of non-small cell lung cancer].Wang Z, Liu H, Zhao R, Zhang H, Liu C, Song Y. Zhongguo Fei Ai Za Zhi. 2013;16(4):191-6.

2023

• Multiperspective quantitative tumor-stroma ratio reveals histological areas associated with poor outcomes in oral squamous cell carcinoma. Wang S, Si Q, Wu Y, Sun Y, Zhang W, Huang X, Zeng T, Chen S, Yang X, Ni Y, Hu Q. Cancer Med. 2023 Jun;12(11):12161-12172. doi: 10.1002/cam4.5909. Epub 2023 May 15.
• Tumor-stroma ratio is a promising prognostic classifier in oropharyngeal cancer. Almangush A, Jouhi L, Haglund C, Hagström J, Mäkitie AA, Leivo I. Hum Pathol. 2023 Jun;136:16-24. doi: 10.1016/j.humpath.2023.03.010.
• Tumor-Stroma Ratio in Basaloid and Conventional Laryngeal Squamous Cell Carcinoma: Prognostic Significance and Concordance in Paired Biopsies and Surgical Samples. Marioni G, Taboni S, Sbaraglia M, Franz L, Saccardo T, Colombo A, Zimello C, Frigo AC, Ferrari M, Alessandrini L. Cancers (Basel). 2023 Mar 7;15(6):1645. doi: 10.3390/cancers15061645.
• Tumor Microenvironment and Immune Response in Lip Cancer. Gkegka AG, Koukourakis MI, Lambropoulou M, Giatromanolaki A. Cancers (Basel). 2023 Feb 25;15(5):1478. doi: 10.3390/cancers15051478.

2022

• Tumor-stroma ratio can predict lymph-node metastasis in cT1/2N0 oral tongue squamous cell carcinoma independent of tumor budding grade. Sakai T, Saito Y, Tateishi Y, Yamazawa S, Fukuoka O, Kobayashi K, Omura G, Akashi K, Yoshida M, Ando M, Ebihara Y, Yamasoba T. Int J Clin Oncol. 2022 Oct 5. doi: 10.1007/s10147-022-02249-y. Epub ahead of print
• Exploring the combination of tumor-stroma ratio, tumor-infiltrating lymphocytes, and tumor budding with WHO histopathological grading on early-stage oral squamous cell carcinoma prognosis. Silva GVD, da Silva Dolens E, Paranaíba LMR, Ayroza ALC, Gurgel Rocha CA, Almangush A, Salo T, Brennan PA, Coletta RD. J Oral Pathol Med. 2022 Sep 23. doi: 10.1111/jop.13359. Epub ahead of print.
• Prognostic and clinicopathological significance of tumor-stroma ratio in head and neck squamous cell carcinoma: A systematic review. Morais EF, Morais HG, Martins HD, Carlan LM, Costa AD, Freitas RD. Med Oral Patol Oral Cir Bucal. 2022 Jul 1;27(4):e301-e309. doi: 10.4317/medoral.24922
• Tumor-stroma ratio, neoangiogenesis and prognosis in laryngeal carcinoma. A pilot study on preoperative biopsies and matched surgical specimens. Alessandrini L, Ferrari M, Taboni S, Sbaraglia M, Franz L, Saccardo T, Del Forno BM, Agugiaro F, Frigo AC, Dei Tos AP, Marioni G. Oral Oncol. 2022 Sep;132:105982. doi: 10.1016/j.oraloncology.2022.105982. Epub 2022 Jun 24
• Tumor-stroma ratio is a crucial histological predictor of occult cervical lymph node metastasis and survival in early-stage (cT1/2N0) oral squamous cell carcinoma. Huang S, Cai H, Song F, Zhu Y, Hou C, Hou J. Int J Oral Maxillofac Surg. 2022 Apr;51(4):450-458.
• Prognostic value of tumor-stroma ratio in oral carcinoma: Role of cancer-associated fibroblasts. Shang Z, Qiu J, Jiang E. Oral Dis. 2022 Apr 7.
• Associations Between ADC and Tumor Infiltrating Lymphocytes, Tumor-Stroma Ratio and Vimentin Expression in Head and Neck Squamous Cell Cancer. Meyer HJ, Höhn AK, Surov A. Acad Radiol. 2022 Mar;29 Suppl 3:S107-S113.
• Emerging histopathologic markers in early-stage oral tongue cancer: A systematic review and meta-analysis. Elseragy A, Bello IO, Wahab A, Coletta RD, Mäkitie AA, Leivo I, Almangush A, Salo T. Head Neck. 2022 Jun;44(6):1481-1491.

2021

• Associations between dynamic-contrast enhanced MRI and tumor infiltrating lymphocytes and tumor-stroma ratio in head and neck squamous cell cancer. Meyer HJ, Höhn AK, Surov A. Cancer Imaging. 2021 Nov 20;21(1):60.
• Tumour-stroma ratio is a valuable prognostic factor for oral tongue squamous cell carcinoma. Kang J, Su M, Xu Q, Wang C, Yuan X, Han Z. Oral Dis. 2021 Aug 29.
• Tumor-stroma ratio is a crucial histological predictor of occult cervical lymph node metastasis and survival in early-stage (cT1/2N0) oral squamous cell carcinoma. Huang S, Cai H, Song F, Zhu Y, Hou C, Hou J. Int J Oral Maxillofac Surg. 2021 Aug 16:S0901-5027(21)00269-1.
• Associations Between ADC and Tumor Infiltrating Lmphocytes, Tumor-Stroma Ratio and Vimentin Expression in Head and Neck Squamous Cell Cancer. Meyer HJ, Höhn AK, Surov A. Acad Radiol. 2021 Jun 30:S1076-6332(21)00222-1
• Assessment of Histological Features in Squamous Cell Carcinoma Involving Head and Neck Skin and Mucosa. Caruntu A, Moraru L, Lupu M, Ciubotaru DA, Dumitrescu M, Eftimie L, Hertzog R, Zurac S, Caruntu C, Voinea OC. J Clin Med. 2021 May 27;10(11):2343
• Histogram parameters derived from T1 and T2 weighted images correlate with tumor infiltrating lymphocytes and tumor-stroma ratio in head and neck squamous cell cancer. Meyer HJ, Höhn AK, Surov A. Magn Reson Imaging. 2021 May 7:S0730-725X(21)00077-1.
• Proposal of a scoring system for predicting pathological risk based on a semiautomated analysis of whole slide images in oral squamous cell carcinoma. Sung YE, Kim MS, Lee YS. Head Neck. 2021 May;43(5):1581-1591.
• Biopsy quality is essential for preoperative prognostication in oral tongue cancer. Bello IO, Wennerstrand PM, Suleymanova I, Siponen M, Qannam A, Nieminen P, Leivo I, Almangush A, Salo T. APMIS. 2021 Mar;129(3):118-127.

2020

• Clinicopathological correlation of tumor-stroma ratio and inflammatory cell infiltrate with tumor grade and lymph node metastasis in squamous cell carcinoma of buccal mucosa and tongue in 41 cases with review of literature. Rani P, Gupta AJ, Mehrol C, Singh M, Khurana N, Passey JC. J Cancer Res Ther. 2020 Apr-Jun;16(3):445-451.
• Addition of the tumour-stroma ratio to the 8th edition American Joint Committee on Cancer staging system improves survival prediction for patients with oral tongue squamous cell carcinoma. Mascitti M, Zhurakivska K, Togni L, Santarelli A, Troiano G et al. Histopathology. 2020 Jul 7. doi: 10.1111/his.14202. Epub ahead of print. PMID: 32633006.
• Histological characteristics of early-stage oral tongue cancer in young versus older patients: A multicenter matched-pair analysis. Bello IO, Almangush A, Heikkinen I, Haglund C, Coletta RD, et al. Oral Dis. 2020 Jan 29
• Prognostication of oral squamous cell carcinoma patients based on tumor-stroma ratio and tumor budding. Dourado MR, Miwa KYM, Hamada GB, Paranaíba LMR, Sawazaki-Calone Í, et al. Histopathology. 2020 Jan 27

2019

• Prognostic significance of tumor budding, tumor-stroma ratio, cell nests size, and stroma type in laryngeal and pharyngeal squamous cell carcinomas. Karpathiou G, Vieville M, Gavid M, Camy F, Dumollard JM, et al. Head Neck. 2019 Jan;1-10

2018

• Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers. Almangush A, Heikkinen I, Bakhti N, Makinen LK, Kauppila JH, Pukkila M, et al. Histopathology. 2018.
• Prognostic impact of tumor-stroma ratio in oral squamous cell carcinoma – A pilot study. Niranjan KC, Sarathy NA. Annals of Diagnostic Pathology 2018; 35:56-61.

2014

• The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer. Oncol Res Treat. Zhang XL, Jiang C, Zhang ZX, Liu F, Zhang F, Cheng YF. 2014;37(9):480-4.

2023

• Increases prognostic value of clinical-pathological nomogram in patients with esophageal squamous cell carcinoma. Hu JF, Song X, Zhong K, Zhao XK, Zhou FY, Xu RH, Li JL, Wang XZ, Li XM, Wang PP, Lei LL, Wei MX, Wang R, Fan ZM, Han XN, Chen Y, Li LY, Ji JJ, Yang YZ, Li B, Yang MM, Yang HJ, Chang FB, Ren JL, Zhou SL, Wang LD. Front Oncol. 2023 Feb 14;13:997776. doi: 10.3389/fonc.2023.997776.

2021

• The prognostic value of tumor-stromal ratio combined with TNM staging system in esophagus squamous cell carcinoma. He R, Li D, Liu B, Rao J, Meng H, Lin W, Fan T, Hao B, Zhang L, Lu Z, Feng H, Zhang Z, Yuan J, Geng Q. J Cancer. 2021 Jan 1;12(4):1105-1114.

2020

• The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer. Van Pelt GW, Krol JA, Lips IM, Peters FP, van Klaveren D, et al. Clin Transl Radiat Oncol. 2019 Nov 27;20:39-44

2016

• Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Hale MD, Nankivell M, Hutchins GG, Stenning SP, Langley RE, Mueller W, et al. Oncotarget. 2016;7(47):77565-75.

2012

• Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. Wang K, Ma W, Wang J, Yu L, Zhang X, Wang Z, et al. J Thorac Oncol. 2012;7(9):1457-61.

2011

• Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. Courrech Staal EF, Smit VT, van Velthuysen ML, Spitzer-Naaykens JM, Wouters MW, Mesker WE, et al. Eur J Cancer. 2011;47(3):375-82.

2010

• The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Courrech Staal EF, Wouters MW, van Sandick JW, Takkenberg MM, Smit VT, Junggeburt JM, et al. Eur J Cancer. 2010;46(4):720-8.

2023

• The Clinical Impact of the Tumor Stroma Ratio in Gastrointestinal Cancer Treatment. Aoyama T, Hashimoto I, Oshima T. Anticancer Res. 2023 May;43(5):1877-1883. doi: 10.21873/anticanres.16346. PMID: 37097668.

2022

• Calculated Tumor-Associated Neutrophils Are Associated with the Tumor-Stroma Ratio and Predict a Poor Prognosis in Advanced Gastric Cancer. Kim EY, Abdul-Ghafar J, Chong Y, Yim K. Biomedicines. 2022 Mar 18;10(3):708.

2021

• Deep learning-based virtual cytokeratin staining of gastric carcinomas to measure tumor-stroma ratio. Hong Y, Heo YJ, Kim B, Lee D, Ahn S, Ha SY, Sohn I, Kim KM. Sci Rep. 2021 Sep 28;11(1):19255.

2020

• Gastric cancer nodal tumour-stroma ratios influence prognosis. Huang J, Yang B, Tan J, Zeng J, Zhong L, Liu X, Han F. Br J Surg. 2020 Oct 14

2019

• Tumour-stroma ratio and 5-year mortality in gastric adenocarcinoma: a systematic review and meta-analysis. Kemi N, Eskuri M, Kauppila JH. Sci Rep. 2019 Nov 5;9(1):16018

2018

• Tumor microenvironmental factors have prognostic significances in advanced gastric cancer.Ahn B, Chae YS, Kim CH, Lee Y, Lee JH, Kom JY. APMIS (Journal of pathology, microbiology and immunology). Sept 2018
• Tumour-stroma ratio and prognosis in gastric adenocarcinoma.Kemi N, Eskuri M, Herva A, Leppänen J, Huhta H, Helminen O, et al. British Journal of Cancer. 2018

2017

• The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system.Peng C, Liu J, Yang G, Li Y. J Gastroenterol. 2017.
• Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients.Aurello P, Berardi G, Giulitti D, Palumbo A, Tierno SM, Nigri G, et al. Surgeon. 2017 Dec; 15(6):329-335.
• Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas.Lee D, Ham IH, Son SY, Han SU, Kim YB, Hur H.Gastric Cancer. 2017 Jul;20(4):591-601.

2023

• The tumor-stroma ratio and the immune microenvironment improve the prognostic prediction of pancreatic ductal adenocarcinoma. Lu M, Zou Y, Fu P, Li Y, Wang P, Li G, Luo S, Chen Y, Guan G, Zhang S, Chen L. Discov Oncol. 2023 Jul 5;14(1):124. doi: 10.1007/s12672-023-00744-w. PMID: 37405518.
•  Tumor-stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma. Wang D, Luo J, Tao Y.BMC Cancer. 2023 May 12;23(1):434. doi: 10.1186/s12885-023-10859-6.

2022

• Prognostic significance of tumour budding, tumour-stroma ratio and desmoplastic stromal reaction in gall bladder carcinoma. Goyal S, Banga P, Meena N, Chauhan G, Sakhuja P, Agarwal AK. J Clin Pathol. 2021 Dec 1:jclinpath-2021-207957. doi: 10.1136/jclinpath-2021-207957. Epub ahead of print
• Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer. Sasaki T, Nishiwada S, Nakagawa K, Nagai M, Terai T, Hokuto D, Yasuda S, Matsuo Y, Doi S, Sho M. Int J Clin Oncol. 2022 May;27(5):948-957.
• Is the tumor-stroma ratio a prognostic factor in gallbladder cancer? Uzun MA, Tilki M, Gönültaş A, Aker F, Kayaoglu SA, Okuyan GÇ. Rev Assoc Med Bras (1992). 2022 May;68(5):664-669.

2021

• CT Radiomics and Machine-Learning Models for Predicting Tumor-Stroma Ratio in Patients With Pancreatic Ductal Adenocarcinoma. Meng Y, Zhang H, Li Q, Liu F, Fang X, Li J, Yu J, Feng X, Zhu M, Li N, Jing G, Wang L, Ma C, Lu J, Bian Y, Shao C. Front Oncol. 2021 Nov 8;11:707288.
• Magnetic Resonance Radiomics and Machine-learning Models: An Approach for Evaluating Tumor-stroma Ratio in Patients with Pancreatic Ductal Adenocarcinoma. Meng Y, Zhang H, Li Q, Liu F, Fang X, Li J, Yu J, Feng X, Lu J, Bian Y, Shao C. Acad Radiol. 2021 Sep 22:S1076-6332(21)00369-X

2020

• Pros and Cons: High Proportion of Stromal Component Indicates Better Prognosis in Patients With Pancreatic Ductal Adenocarcinoma-A Research Based on the Evaluation of Whole-Mount Histological Slides. Li B, Wang Y, Jiang H, Li B, Shi X, Gao S, Ni C, Zhang Z, Guo S, Xu J, Jin G. Front Oncol. 2020 Aug 21;10:1472.
• Prognostic effects of histology-based tumour microenvironment scores in resected distal bile duct cancer. Hwang HW, Kim JY, Lee SE, Choi YS, Hong SH, Lee TJ, Kim MK, Park ES, Hong SA. Histopathology. 2020 Sep;77(3):402-412.
• Tumour budding and tumour-stroma ratio in hepatocellular carcinoma. Kairaluoma V, Kemi N, Pohjanen VM, Saarnio J, Helminen O. Br J Cancer. 2020 Jul;123(1):38-45. doi: 10.1038/s41416-020-0847-1.

2019

• Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Leppänen J, Lindholm V, Isohookana J, Haapasaari KM, Karihtala P, et al. Pancreas. 2019 Jan;48(1):43-48.

2017

• Prognostic significance of the tumor-stroma ratio in gallbladder cancer. Li H, Yuan SL, Han ZZ, Huang J, Cui L, et al. Neoplasma 64; 2017.

2015

• Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation. Lv Z, Cai X, Weng X, Xiao H, Du C, Cheng J, et al. Surgery 2015;158(1):142-50.

2022

• The PDGF Family Is Associated with Activated Tumor Stroma and Poor Prognosis in Ovarian Cancer. Li J, Zhi X, Sun Y, Chen M, Yao L. Dis Markers. 2022 Sep 26;2022:5940049

2020

• The tumor-stroma ratio is an independent predictor of survival in patients with 2018 FIGO stage IIIC squamous cell carcinoma of the cervix following primary radical surgery. Zong L, Zhang Q, Kong Y, Yang F, Zhou Y, et al. Gynecol Oncol. 2020 Mar;156(3):676-681

2019

• Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer. Lou E, Vogel RI, Hoostal S, et al. JAMA Oncol. 2019;5(8):1222-1224.

2015

• Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer. Chen Y, Zhang L, Liu W, Liu X. Biomed Res Int. 2015;2015:589301.
• Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. Pongsuvareeyakul T, Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Intaraphet S, Siriaunkgul S. Asian Pac J Cancer Prev 2015; 16 (10):4363-4368.
• The prognostic significance of tumour-stroma ratio in endometrial carcinoma. Panayiotou H, Orsi NM, Thygesen HH, Wright AI, Winder M, Hutson R, et al. BMC Cancer. 2015;15:955.

2014

• Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma. Liu J, Liu J, Li J, Chen Y, Guan X, Wu X, et al. Gynecol Oncol. 2014;132(1):81-6.

2022

• The tumour-associated stroma correlates with poor clinical outcomes and immunoevasive contexture in patients with upper tract urothelial carcinoma: results from a multicenter real-world study (TSU-01 Study). Xu L, Zhong W, Li C, Hong P, Xia K, Lin R, Cheng S, Wang B, Yang M, Chen J, Ma L, Li X, Zhou L, Huang J, Lin T. Br J Cancer. 2022 Nov 17. doi: 10.1038/s41416-022-02049-1. Epub ahead of print
• A classification based on tumor-stroma ratio and tumor budding for patients with muscle-invasive bladder cancer. Liu J, Li C, Huang K, Aldanakh A, Yang D, Wang J, Sun X, Song X. Expert Rev Anticancer Ther. 2022 Mar;22(3):323-330.

2021

• Tumor-stroma ratio as a new prognosticator for pseudomyxoma peritonei: a comprehensive clinicopathological and immunohistochemical study. Ma R, Lin YL, Li XB, Yan FC, Xu HB, Peng Z, Li Y. Diagn Pathol. 2021 Dec 13;16(1):116.

2019

• The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma. Zou MX, Zheng BW, Liu FS, Wang XB, Hu JR, Huang W, et al. Neurosurgery. 2019 Sep 9.

Meta-analysis

• Prognostic Value of Tumor-Stroma Ratio in Rectal Cancer: A Systematic Review and Meta-analysis. Zhu Y, Jin Z, Qian Y, Shen Y, Wang Z. Front Oncol. 2021 May 26;11:685570
• Clinical significance of tumor-stroma ratio in head and neck cancer: a systematic review and meta-analysis. Almangush A, Alabi RO, Troiano G, Coletta RD, Salo T, Pirinen M, Mäkitie AA, Leivo I. BMC Cancer. 2021 Apr 30;21(1):480.
• Tumor-stroma ratio (TSR) as a potential novel predictor of prognosis in digestive system cancers: A meta-analysis. Zhang R, Song W, Wang K, Zou S. Clin Chim Acta. 2017;472:64-8.
• Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis.Wu J, Liang C, Chen M, Su W. Oncotarget. 2016 Oct 18;7(42):68954-68965.

Reviews

• The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, Tollenaar RAEM, Mesker WE. Breast Cancer Res Treat. 2018 Oct
• The tumour-stroma ratio in colon cancer; the biological role and its prognostic impact. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken J, Tollenaar R, et al. Histopathology. 2018 Aug;73(2):197-206.